罗氏的瓦米基巴特改善了视力,并减少了眼睛胀的卵膜斑点患者, 显示作为非类固醇治疗的希望. Roche's vamikibart improved vision and reduced eye swelling in uveitic macular edema patients, showing promise as a non-steroid treatment.

Roche介绍了Vamikibart的第三阶段试验结果,Vamikibart是一种调查性方法,用于调查冲积结膜肿水肿,与安慰剂相比,视力明显改善,眼肿减少。 Roche presented phase III trial results for vamikibart, an investigational treatment for uveitic macular edema, showing significant vision improvement and reduced eye swelling compared to placebo. MEERKAT和SANDCAT的试验都表明在视觉敏锐性和肌肉厚度降低方面取得了有意义的进展,尽管SANDCAT没有达到主要终点。 Both MEERKAT and SANDCAT trials demonstrated meaningful gains in visual acuity and decreased macular thickness, though primary endpoints were not met in SANDCAT. 该药物一般很安全,严重副作用的发生率较低。 The drug was generally safe, with low rates of serious side effects. Roche计划与监管者分享结果,因为Vamikibart可以提供一种替代当前注射的非类固醇替代品。 Roche plans to share results with regulators, as vamikibart could offer a non-steroid alternative to current injections.